Medical application of the monoclonal antibody SKM9-2 against sialylated HEG1, a new precision marker for malignant mesothelioma

Proceedings of the Japan Academy 2023 [Link] Shoutaro Tsuji, Kohzoh Imai Abstract Malignant pleural mesothelioma (MPM) is an aggressive tumor of the pleural cavity. Pathologically distinguishing MPM from other pleural lesions is often difficult. We searched for marker antigens to facilitate the pathological diagnosis of MPM and found useful markers for the pathological detection of…

Read More

Identification of Highly Sensitive Pleural Effusion Protein Biomarkers for Malignant Pleural Mesothelioma by Affinity-Based Quantitative Proteomics

Cancers 2023 January 19 [Link] Nicolai B Palstrøm, Martin Overgaard, Peter Licht, Hans C Beck Abstract Malignant pleural mesothelioma (MPM) is an asbestos-associated, highly aggressive cancer characterized by late-stage diagnosis and poor prognosis. Gold standards for diagnosis are pleural biopsy and cytology of pleural effusion (PE), both of which are limited by low sensitivity and…

Read More

CD70 and PD-L1 (CD274) co-expression predicts poor clinical outcomes in patients with pleural mesothelioma

The Journal of Pathology. Clinical Research 2023 February 8 [Link] Shingo Inaguma, Akane Ueki, Jerzy Lasota, Masayuki Komura, Asraful Nahar Sheema, Piotr Czapiewski, Renata Langfort, Janusz Rys, Joanna Szpor, Piotr Waloszczyk, Krzysztof Okoń, Wojciech Biernat, David S Schrump, Raffit Hassan, Markku Miettinen, Satoru Takahashi Abstract Diffuse pleural mesothelioma (PM) is a highly aggressive tumour typically…

Read More

The Predictive Value of ERCC1, RRM1, and Thymidylate Synthase in Advanced Malignant Pleural Mesothelioma Patients Treated with Platinum-Based Chemotherapy

Asian Pacific Journal of Cancer Prevention 2023 January 1 [Link] Nagwa Ismail Wahba, Ola Khorshid, Fatma Abo Elkasem, Abeer Bahnassy, Rabab Gaafer Abstract Background: A rare yet severe neoplasia called malignant pleural mesothelioma (MPM) typically manifests itself in advanced stages. Despite some improvements in the treatment of patients with MPM, this malignancy continues to have…

Read More

Immunohistochemistry for Claudin-4 and BAP1 in the Differential Diagnosis between Sarcomatoid Carcinoma and Sarcomatoid Mesothelioma

Diagnostics 2023 January [Link] Lina Zuccatosta, Tommaso Bizzarro, Giulio Rossi, Graziana Gallo, Stefano Gasparini, Andrea Ambrosini-Spaltro Abstract (1) Background. In the differential diagnosis between sarcomatoid carcinoma (SC) and sarcomatoid mesothelioma (SM), we aimed to investigate the role of Claudin-4 and BAP1, a panel recently used to distinguish conventional carcinoma from epithelioid mesothelioma. (2) Methods. We…

Read More

Carbon-ion beam irradiation in combination with cisplatin effectively suppresses xenografted malignant pleural mesothelioma

American Journal of Cancer Research 2022 December 15 [Link] Sei Sai, Taiju Yamada, Keiko Ito, Nobuyuki Kanematsu, Masao Suzuki, Mitsuhiro Hayashi, Masashi Koto Abstract Malignant pleural mesothelioma (MPM) is a rare aggressive cancer. This study investigated the growth-inhibitory effects of the combination of carbon ion beam irradiation (IR) and cisplatin (CDDP) on MPM xenografts. Carbon-ion…

Read More

AXL and MET Tyrosine Kinase Receptors Co-Expression as a Potential Therapeutic Target in Malignant Pleural Mesothelioma

Journal of Personalized Medicine 2022 December 2 [Link] Federica Zito Marino, Carminia Maria Della Corte, Vincenza Ciaramella, Stefania Erra, Andrea Ronchi, Alfonso Fiorelli, Giovanni Vicidomini, Mario Santini, Giosuè Scognamiglio, Floriana Morgillo, Fortunato Ciardiello, Renato Franco, Marina Accardo Abstract Malignant pleural mesothelioma (MPM) is a highly lethal malignancy that unfortunately cannot benefit from molecularly targeted therapies.…

Read More

NR4A3 fusions characterize a distinctive peritoneal mesothelial neoplasm of uncertain biological potential with pure adenomatoid/microcystic morphology

Genes, Chromosomes, and Cancer 2022 December 16 [Link] Abbas Agaimy, Luka Brcic, Laurence M Briski, Yin P Hung, Michael Michal, Michal Michal, G Petur Nielsen, Robert Stoehr, Andrew E Rosenberg Abstract A focal adenomatoid-microcystic pattern is not uncommon in peritoneal mesothelioma, but tumors composed almost exclusively of this pattern are distinctly rare and have not…

Read More

Usefulness of NF2 hemizygous loss detected by fluorescence in situ hybridization in diagnosing pleural mesothelioma in tissue and cytology material: A multi-institutional study

Lung Cancer 2022 November 19 [Link] Prakasit Sa-Ngiamwibool, Makoto Hamasaki, Yoshiaki Kinoshita, Shinji Matsumoto, Ayuko Sato, Tohru Tsujimura, Kunimitsu Kawahara, Takahiko Kasai, Kei Kushitani, Yukio Takeshima, Kenzo Hiroshima, Akinori Iwasaki, Kazuki Nabeshima Abstract Objectives: BAP1, CDKN2A, and NF2 are the most frequently altered genes in pleural mesotheliomas (PM). Discriminating PM from benign mesothelial proliferation (BMP)…

Read More

Histopathological and immunohistochemical features of 14 peritoneal mesotheliomas with clinical outcomes and recent updates

Journal of Cancer Research and Therapeutics 2022 Oct-Dec [Link] Srushti Karmarkar, Bharat Rekhi, Kedar K Deodhar, Santosh Menon Abstract Background: Malignant peritoneal mesotheliomas (MPMs) are rare tumors with overlapping clinical and histopathological features, especially with epithelial ovarian carcinomas (EOCs). There is no substantial documentation on these rare tumors from our country. Objective: To study the…

Read More